CVS/Caremark Merger Closes, Creating the Nation's Leading Pharmacy Services Company
22 3์ 2007 - 4:01PM
Business Wire
CVS Corporation and Caremark Rx, Inc. today announced that they
have formally closed their transformative merger of equals,
creating the nation๏ฟฝs premier integrated pharmacy services
provider. The combined company, renamed CVS/Caremark Corporation
(NYSE: CVS), unifies the nation๏ฟฝs largest pharmacy chain with a
leading pharmaceutical services company, creating the opportunity
to deliver unique products and services that will help manage costs
for employers and improve access and choice for consumers. ๏ฟฝToday๏ฟฝs
close of our landmark merger will enable us to begin delivering
substantial benefits to shareholders, customers and employees,๏ฟฝ
said Tom Ryan, CVS/Caremark๏ฟฝs President and Chief Executive
Officer. ๏ฟฝCVS/Caremark will offer end-to-end services, from plan
design to prescription fulfillment, as well as the opportunity to
improve clinical outcomes, which will result in better control over
healthcare costs for employers and plan providers. The company will
improve the delivery of pharmacy services and healthcare decision
making, enabling consumers to benefit from unparalleled access,
greater convenience and more choice. We look forward to
capitalizing on the tremendous opportunity ahead of us to improve
the delivery of pharmacy services.๏ฟฝ ๏ฟฝAfter months of planning, we
are excited to realize our shared vision of creating the premier
provider of pharmacy services in the nation,๏ฟฝ said Mac Crawford,
Chairman of CVS/Caremark. ๏ฟฝTogether we will deliver unique products
and services that are responsive to the needs of employers, health
plans and consumers, and do it in more convenient and flexible ways
that allows consumers to take more control of their healthcare
needs.๏ฟฝ In light of the closing, CVS/Caremark will commence a cash
tender offer in approximately five business days for 150 million,
or about 10 percent, of its outstanding shares at a fixed price of
$35 per share. The combined company will trade on the New York
Stock Exchange under the symbol ๏ฟฝCVS.๏ฟฝ Effective today, trading in
Caremark stock (NYSE: CMX) has been discontinued. About
CVS/Caremark CVS/Caremark is the nation's premier integrated
pharmacy services provider, combining one of the nation's leading
pharmaceutical services companies with the country๏ฟฝs largest
pharmacy chain. The company fills or manages more than one billion
prescriptions per year, more than any other pharmacy services
provider. CVS/Caremark drives value for pharmacy services customers
by effectively managing pharmaceutical costs and improving
healthcare outcomes through its 6,200 CVS/pharmacy stores; its
pharmacy benefit management, mail order and specialty pharmacy
division, Caremark Pharmacy Services; its retail-based health
clinic subsidiary, MinuteClinic; and its online pharmacy, CVS.com.
General information about CVS/Caremark is available through the
Investor Relations portion of the Company's website, at
http://investor.cvs.com, as well as through the pressroom portion
of the Company's website, at www.cvs.com/pressroom. Certain
Information Regarding the Tender Offer After Closing of the Merger
The information in this press release describing CVS๏ฟฝ planned
tender offer following closing of the CVS/Caremark merger is for
informational purposes only and does not constitute an offer to buy
or the solicitation of an offer to sell shares of CVS/Caremark๏ฟฝs
common stock in the tender offer. The tender offer will be made
only pursuant to the Offer to Purchase and the related materials
that CVS/Caremark will distribute to its shareholders. Shareholders
should read the Offer to Purchase and the related materials
carefully because they contain important information, including the
various terms and conditions of the tender offer. Subsequent to the
commencement of the tender offer, shareholders of CVS/Caremark will
be able to obtain a free copy of the Tender Offer Statement on
Schedule TO, the Offer to Purchase and other documents that
CVS/Caremark will be filing with the Securities and Exchange
Commission from the Commission๏ฟฝs website at www.sec.gov.
Shareholders may also obtain a copy of these documents, without
charge, from Morrow & Co., Inc., the information agent for the
tender offer, toll free at 1 (800) 245-1502 when these documents
become available. Shareholders are urged to carefully read these
materials prior to making any decision with respect to the tender
offer. Shareholders and investors who have questions or need
assistance may call Morrow & Co., Inc., the information agent
for the tender offer, toll free at 1 (800) 245-1502. Cautionary
Statement Regarding Forward-Looking Statements This document
contains certain forward-looking statements about CVS and Caremark.
When used in this document, the words "anticipates", "may", "can",
"believes", "expects", "projects", "intends", "likely", "will", "to
be" and any similar expressions and any other statements that are
not historical facts, in each case as they relate to CVS or
Caremark or to the combined company, the management of either such
company or the combined company or the transaction are intended to
identify those assertions as forward-looking statements. In making
any of those statements, the person making them believes that its
expectations are based on reasonable assumptions. However, any such
statement may be influenced by factors that could cause actual
outcomes and results to be materially different from those
projected or anticipated. These forward-looking statements,
including, without limitation, statements relating to anticipated
accretion, return on equity, cost synergies, incremental revenues
and new products and offerings, are subject to numerous risks and
uncertainties. There are various important factors that could cause
actual results to differ materially from those in any such
forward-looking statements, many of which are beyond the control of
CVS and Caremark, including macroeconomic condition and general
industry conditions such as the competitive environment for retail
pharmacy and pharmacy benefit management companies, regulatory and
litigation matters and risks, legislative developments, changes in
tax and other laws and the effect of changes in general economic
conditions. The actual results or performance by CVS or Caremark or
the combined company, and issues relating to the transaction, could
differ materially from those expressed in, or implied by, any
forward-looking statements relating to those matters. Accordingly,
no assurances can be given that any of the events anticipated by
the forward-looking statements will transpire or occur, or if any
of them do so, what impact they will have on the results of
operations or financial condition of CVS or Caremark, the combined
company or the transaction.
Caremark RX (NYSE:CMX)
๊ณผ๊ฑฐ ๋ฐ์ดํฐ ์ฃผ์ ์ฐจํธ
๋ถํฐ 11์(11) 2024 ์ผ๋ก 12์(12) 2024
Caremark RX (NYSE:CMX)
๊ณผ๊ฑฐ ๋ฐ์ดํฐ ์ฃผ์ ์ฐจํธ
๋ถํฐ 12์(12) 2023 ์ผ๋ก 12์(12) 2024